Dickmeyer Boyce Financial Management Inc. Buys Shares of 6,007 Novartis AG $NVS

Dickmeyer Boyce Financial Management Inc. purchased a new position in Novartis AG (NYSE:NVS) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 6,007 shares of the company’s stock, valued at approximately $918,000.

A number of other large investors also recently modified their holdings of the business. Arlington Trust Co LLC acquired a new stake in shares of Novartis in the fourth quarter worth $25,000. Archer Investment Corp raised its stake in Novartis by 93.0% during the 1st quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after purchasing an additional 80 shares during the last quarter. CrossGen Wealth LLC acquired a new position in Novartis during the 4th quarter valued at $28,000. Bank of Jackson Hole Trust boosted its holdings in Novartis by 425.0% in the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 187 shares during the period. Finally, Measured Wealth Private Client Group LLC bought a new stake in Novartis in the 3rd quarter valued at $33,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NVS. Morgan Stanley boosted their price objective on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Citigroup reiterated a “buy” rating on shares of Novartis in a research note on Wednesday. Finally, Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $141.20.

Novartis Stock Up 2.1%

NVS opened at $156.32 on Friday. The firm has a market cap of $298.29 billion, a price-to-earnings ratio of 23.58, a PEG ratio of 2.65 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.65 and a current ratio of 0.86. The firm’s 50-day simple moving average is $151.81 and its 200-day simple moving average is $152.11. Novartis AG has a twelve month low of $112.34 and a twelve month high of $170.46.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The firm had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. Equities research analysts anticipate that Novartis AG will post 8.75 EPS for the current fiscal year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.